Both experimental [29] and clinical studies confirm T-DXd’s efficacy in HER2-positive, trastuzumab-resistant breast cancers, as well as HER2-mutant non-small-cell lung cancer [30–32]. Here, ERBB2 is linked to breast carcinoma.